Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Mark Singleton Biography and Net Worth

Sr. VP of Bioventus

Mark Singleton serves as the Company’s Senior Vice President, Chief Financial Officer and Principle Accounting Officer.

Mr. Singleton has more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Mark was also involved in initiating the Vascular Solutions acquisition which became a separate business unit at Teleflex.

Previous to this role, Mr. Singleton served as Vice President of Finance of Teleflex’s Vascular business where he had financial responsibility for the $1.7 billion Americas business. Prior to Teleflex, he spent nearly two decades at Lenovo/IBM, where he held a number of senior leadership positions, including EMEA CFO, Western Europe CFO, North America CFO, and Think Business Group CFO.

Mr. Singleton earned his Master of Business Administration from Duke University’s Fuqua School of Business and completed his Bachelor of Science in Finance from Purdue University.

How old is Mark Singleton?: Mr. Singleton is currently 54 years old. There are 3 older executives and no younger executives at Bioventus. The oldest executive at Bioventus is Mr. Anthony D'Adamio, Senior VP, General Counsel & Corporate Secretary, who is 63 years old. Learn More on Mark Singleton's age.
How do I contact Mark Singleton?: The corporate mailing address for Mr. Singleton and other Bioventus executives is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. Bioventus can also be reached via phone at 919-474-6700 and via email at [email protected]. Learn More on Mark Singleton's contact information.
Has Mark Singleton been buying or selling shares of Bioventus?: Mark Singleton has not been actively trading shares of Bioventus within the last three months. Learn More on Mark Singleton's trading history.
Who are Bioventus' active insiders?: Bioventus' insider roster includes Anthony D'Adamio (SVP), Kenneth Reali (CEO), and Mark Singleton (Sr. VP). Learn More on Bioventus' active insiders.
Are insiders buying or selling shares of Bioventus?: In the last twelve months, Bioventus insiders bought shares 2 times. They purchased a total of 105,500 shares worth more than $902,025.00. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 55,904 shares worth more than $311,026.34. The most recent insider tranaction occured on August, 19th when Director John A Bartholdson bought 25,500 shares worth more than $218,025.00. Insiders at Bioventus own 32.9% of the company. Learn More about insider trades at Bioventus.
Information on this page was last updated on 8/19/2024.

Mark Singleton Insider Trading History at Bioventus

Mark Singleton Buying and Selling Activity at Bioventus

Bioventus Company Overview

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Today's Range

Now: $11.24

$10.96

$11.30

50 Day Range

MA: $11.97

$10.23

$13.71

2 Week Range

Now: $11.24

$3.64

$14.38

Volume

278,283 shs

Average Volume

491,268 shs

Market Capitalization

$912.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.